# Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities (2025 Version)

## TL;DR

This paper presents an expert consensus on diagnosing and treating non-small cell lung cancer with MET gene abnormalities, including various mutation types and treatment strategies.

## Contribution

The 2025 expert consensus provides updated clinical guidance for MET-abnormal NSCLC, integrating recent evidence and practical experience.

## Key findings

- MET gene abnormalities include METex14 skipping mutations, amplifications, fusions, and overexpression.
- Targeted therapies for MET abnormalities show significant clinical benefits in advanced or metastatic NSCLC.
- The consensus aims to standardize diagnosis and treatment to improve patient outcomes.

## Abstract

间质上皮细胞转化因子（mesenchymal-epithelial transition factor, MET）基因位于人类7号染色体上，对细胞的增殖、迁移、侵袭和血管生成等生理过程起着至关重要的调控作用。MET基因是非小细胞肺癌（non-small cell lung cancer, NSCLC）的重要驱动基因之一，其异常形式多样，包括MET 14号外显子（MET exon 14, METex14）跳跃突变、MET基因扩增、MET融合、MET蛋白过表达以及MET活化突变等。随着对MET异常机制的深入理解，针对这些异常的治疗策略日益受到重视，且多项研究已证实携带MET异常的NSCLC患者能从这些治疗中显著获益。中国老年保健协会肺癌专业委员会致力于协助中国医师的临床实践，并为临床工作提供规范化指导，因此组织各专家委员结合临床实践经验并探寻循证医学证据，针对目前MET异常NSCLC诊断和治疗的临床问题给予专业建议，并制定专家共识《MET异常NSCLC诊疗专家共识（2025版）》，以期优化患者的治疗结果。

Key clinical study data on targeted drugs (oral) for the treatment of METex14 skipping mutations in locally advanced or metastatic NSCLC

Key clinical study data of targeted drugs (oral) for treating MET primary amplification in locally advanced or metastatic NSCLC

Key clinical study data of targeted drugs (oral) for treating MET secondary amplification in locally advanced or metastatic NSCLC